RESTORING GLYCEMIC CONTROL
Type 2 Diabetes and other metabolic diseases (such as NASH) are associated with diminishing capacity of the body to control glucose levels. Duodenal Glycemic Control™ is a safe, 30 minute, minimally-invasive therapeutic procedure that uses Digma Medical's product - DiaGone™ to restore the body's natural ability to control glucose, with NO implant.
WHO WE ARE
Digma Medical is a clinical stage medical technology company revolutionizing the treatment of Type 2 Diabetes and other metabolic syndrome disease such as NASH. Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of our patented technology, DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. DiaGone™ is now in
a multi-center clinical study in Spain, Israel and the Czech Republic.
Safe. One-time. No implant.
Diabetes, Now Gone!
DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum.
The Duodenal Glycemic Control™ procedure is a 30 minute GI procedure, in which the gastroenterologist uses DiaGone™ to treat the duodenum for restoring the natural ability of the body to control glucose levels.
SCIENTIFIC ADVISORY BOARD
DAVID CARR-LOCKE, MD
Dr. Carr-Locke is the Clinical Director for the Center for Advanced Digestive Care. He received his medical degree from Cambridge University. He completed his residency and fellowship training at the University of Leicester, England and undertook a clinical research fellowship in gastroenterology at the New England Baptist Hospital in Boston. Dr. Carr-Locke served as Director of the Endoscopy Institute at the Brigham & Women’s Hospital, Boston and faculty at Boston Children’s Hospital and the Dana Farber Cancer Institute and most recently was the Chief for the Division of Digestive Diseases and the Associate Chair of Medicine at Mount Sinai-Beth Israel Medical Center.
JUDITH KORNER, MD, PHD
Dr. Judith Korner, MD, PhD is Professor of Medicine and the Director of the Weight Control Center at the Division of Endocrinology and Metabolism at New York Presbyterian/ Columbia University Medical Center. Dr. Korner received her MD at the College of Physicians and Surgeons of Columbia University where she also obtained her PhD in Biochemistry and Molecular Biophysics in the laboratory of Dr. Richard Axel. She completed her internship and residency in Internal Medicine, served as Chief Medical Resident, and completed her fellowship in Diabetes, Endocrinology and Metabolism at Columbia University Medical Center.
PAUL ZIMMET, MD, PHD
Dr. Paul Zimmet is Professor of Diabetes at Monash University and formerly Director Emeritus, Baker IDI Heart and Diabetes Institute. In 1984, he founded the International Diabetes Institute which merged with the Baker Institute in 2008. He is Honorary President of the International Diabetes Federation and has an extensive international record in diabetes and obesity research, particularly in epidemiology and public health.
ERAN GOLDIN, MD
Dr. Eran Goldin is Professor of Medicine and the Director of the Digestive Disease Institute at Shaare Zedek Medical Center, Jerusalem. Prior to his role in Shaare Zedek, Prof' Goldin was Head of Gastroenterology & Digestive Disease at the Hadassa Medical Center, Jerusalem. Dr. Goldin is a Professor of Medicine in the Hebrew University Hadassah Medical School of Medicine.
RICARDO COHEN, MD
Dr. Cohen is the director for the Center for Obesity and Diabetes at the Oswaldo Cruz German Hospital located in São Paulo, Brazil. Dr. Cohen is also the former president of the Brazilian Society of Bariatric and Metabolic Surgery, and is the current president of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), Latin America Chapter.
PANKAJ JAY PASRICHA, MBBS, MD
Dr. Pasricha is leading the establishment of the Johns Hopkins Center for Neurogastroenterology. Prior to that, he was chief of gastroenterology in Stanford University. Patients with motility disorders as well as diseases ranging from Parkinsons to Autism, and diabetes to obesity, stand to benefit from his research, which focuses on clinical disorders associated with gastroenterological motility, the biology of the enteric nervous system and visceral pain, neural stem cells and technology development associated with endoscopic research and advancements.
LUC VAN GAAL, MD, PHD
Prof. Luc Van Gaal is the Head of the Department of Endocrinology, Metabolism & Clinical Nutrition-Faculty of Medicine of the University Hospital Antwerp, Belgium. He also serves as a Professor of Medicine in the University of Antwerp Medical School. Dr. Van Gaal serves on multiple editorial boards in the area of endocrinology, diabetes, and obesity.
DIGMA MEDICAL TEAM
BOAZ BEHAR, ENG, MBA
Boaz joined Digma as CEO in 2014. Prior to Digma Mr. Behar was founder & CEO of Perseus-BioMed a medtech startup. Earlier, he led the R&D of Identify Software which was acquired for $150M in 2006. Boaz co-founded, and headed the R&D of Farechase which was acquired by Yahoo! in 2003, and earlier has led both software development and business development in Biosense which was acquired by Johnson & Johnson for $427M. Mr. Behar holds Mechanical Engineering and Computer Science degrees cum-laude from the Technion, Haifa, and an Executive MBA from the Recanati Business School of Tel Aviv University.
DR. IRIT YANIV, MD, MBA
Irit Yaniv is an experienced and accomplished senior executive in the medtech industry, and has held CEO positions with medical device companies Impulse Dynamics and MetaCure. In parallel to her position at Digma, Irit is a Venture Partner at Accelmed VC, where she leads the early stage portfolio investments. Dr. Yaniv holds an MD degree from the Ben-Gurion University and an MBA from the Recanati Business School of Tel Aviv University.
DR. BRIAN L. LEVY, MD, FACE
Dr Levy brings over 25 years of clinical and research experiences within the endocrinology, diabetes and metabolism community. Prior to Digma, Dr. Levy was Chief Medical Officer & Worldwide VP of Clinical Affairs of Johnson & Johnson Diabetes Care Companies (Animas, Calibra, LifeScan, JJDI) where he oversaw all of clinical and medical affairs of the group. Before J&J Diabetes Care, Dr. Levy served as Global Medical Affairs Leader for Metabolic Disease at Janssen Pharma at J&J, where he led the INVOKANA (canagliflozin) medical affairs program. Dr. Levy was on faculty at NYU school of medicine, where he remains an attending physician at Bellevue Hospital NYC. Dr. Levy received his BA at Cornell U, his MD from Johns Hopkins University School of Medicine, and completed his residency & fellowship in Endocrinology & Metabolism at NYU Medical Center.
Ilan brings more than 20 years experience in R&D and management in the medical device arena. Prior to joining Digma Medical, he served as the CTO of Exalenz Bioscience Ltd., (TASE:EXEN) and Oridion Medical (SWX:ORIDN). Mr. Ben Oren is the author of more than 40 patents and patent applications in the field of medical technologies and electro-optics. Mr. Ben-Oren holds a master’s degree in applied physics and the science of materials summa-cum-laude from the Hebrew University of Jerusalem.
YANIV KIRMA, ENG
Yaniv has over 15 years of experience in leading large and small scale cross-organizational projects including management of multidisciplinary R&D teams from initial proof of concept throughout the product launch. Prior to joining Digma, Yaniv was VP R&D of Peer-Medical which was merged with Endochoice and acquired by Boston Scientific in 2016.
Mr. Kirma holds a BSc in electrical Engineering and Physics from the Technion, Haifa.
HILA DAGAN, PHD
Hila has over 10 years of experience in medical device regulatory, clinical affairs and quality assurance. Prior to Digma, Hila was VP Clinical and Regulatory affairs in a wearable telemedicine startup where she built and lead the regulatory strategy, clinical affairs and quality system infrastructure. Earlier, Hila was a researcher and project manager in other medical device companies in the field of wound care and stem cells regenerative medicine. Dr. Dagan holds a PhD in Biotechnology from Tel Aviv University in the field of nano-biotechnology.
AVIA HERSCHKOVITZ, PHD
Director of Research & QA Manager
Avia has over 12 years experience in research, animal trials and modeling, in-vivo, ex-vivo & in-vitro experimentation. Prior to Digma Avia was an analyst in a venture capital fund where he was in charge of research & IP. Dr. Herschkovitz holds a PhD in molecular cell biology from the Weizmann Institute of Science in the field of diabetes, obesity and insulin resistance research.